| Identification | Back Directory | [Name]
Resibufogenin | [CAS]
465-39-4 | [Synonyms]
rbg
Respigon
BUFOGENIN
bufogenina
RESIBUFOGENIN
Resibufogeninc
RESIBUFOGENIN95%,97%
Resibufogenin(NSC 90783)
14,15β-Epoxy-3β-hydroxy-5β-bufa-20,22-dienolide
20,22,5BETA-BUFADIENOLID-14BETA,15BETA-EPOXY-3BETA-OL
22-dienolide,14,15-beta-epoxy-3-beta-hydroxy-5-beta-bufa-2
3-beta-hydroxy-14,15-beta-epoxy-5-beta-bufa-20,22-dienolide
14,15-beta-epoxy-3-beta-hydroxy-5-beta-bufa-20,22-dienolide
5-beta-Bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta-hydroxy-
(3BETA,5BETA,15BETA)-14,15EPOXY-3-HYDROXY-5-BUFA-20,22-DIENOLIDE | [Molecular Formula]
C24H32O4 | [MDL Number]
MFCD00210361 | [MOL File]
465-39-4.mol | [Molecular Weight]
384.51 |
| Chemical Properties | Back Directory | [Melting point ]
113-140°/155-168° | [alpha ]
D22 -7.1° (c = 1.259 in chloroform); D16 -5.4° (c = 2.030 in chloroform) | [Boiling point ]
431.17°C (rough estimate) | [density ]
1.0474 (rough estimate) | [refractive index ]
1.4860 (estimate) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMF: 25 mg/mL; DMF:PBS(pH 7.2)(1:1): 0.5 mg/mL; DMSO: 20 mg/mL; Ethanol: 5 mg/mL | [form ]
White to off-white solid. | [pka]
15.14±0.70(Predicted) | [color ]
White to off-white | [Stability:]
Moisture Sensitive | [Major Application]
metabolomics
vitamins, nutraceuticals, and natural products | [InChIKey]
ATLJNLYIJOCWJE-CWMZOUAVSA-N | [SMILES]
C[C@@]12[C@@]3(O[C@@H]3C[C@@H]2C4=COC(C=C4)=O)[C@]5([H])CC[C@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC1 |
| Safety Data | Back Directory | [Safety Statements ]
24/25 | [RIDADR ]
3172 | [WGK Germany ]
WGK 3 | [HazardClass ]
6.1(a) | [PackingGroup ]
II | [HS Code ]
29322090 | [Storage Class]
6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | [Hazard Classifications]
Acute Tox. 2 Dermal
Acute Tox. 2 Inhalation
Acute Tox. 2 Oral | [Toxicity]
LD50 oral in mouse: 59800mg/kg |
| Hazard Information | Back Directory | [Description]
As one of the active components of Bufonis bufa, Resibufogenin is speculated that Etobufaxin can inhibit the proliferation of tumor cells by inducing apoptosis of osteosarcoma cells. | [Uses]
Resibufogenin is used for content determination/identification/pharmacological experiments, etc. | [Definition]
ChEBI: Bufogenin is a steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers. It has a role as an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a steroid lactone and an epoxy steroid. It is functionally related to a bufanolide. | [Biological Activity]
Resibufogenin (Bufogenin, Recibufogenin) is the anticancer component of huachansu cinobufogenin, which triggers necrosis by up-regulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating Ser358 of mixed lineage kinase domain-like protein. It exerts cytotoxic effects by inducing the accumulation of reactive oxygen species (ROS). Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Also it increases Bax/Bcl-2 expression and inhibits protein expression of cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin. | [Pharmacokinetics]
The main pharmacological action of acetobufaxin is anti-tumor. The cinobufavidin injection was separated by modern chromatographic techniques, and the exobufaxin compounds were obtained. The main monomers of exobufaxin were analyzed and identified by HPLC-DAD-FT-ICR-MS. The anti-tumor activity of exobufaxin was screened in vitro, and the pancreatic cancer tumor-bearing nude mouse model was established in vivo to evaluate the efficacy of exobufaxin. | [target]
| Target | Value | RIP3
() | MLK
() | ROS
() | Caspase-3
() | Caspase-8
() | | |
|
|
|